Drug Database · Clinicians

Ondansetron

Brands (60) Ondavell, Egezet, Ondens…Show all

Antiemetic (5-HT3 receptor antagonist); Antiemetic/Antinauseant [serotonin (5HT3) antagonist; and others PH FDA category

Rx · Prescription drug71 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID de72f1ec-75dd-4659-a1a0-32b28b72c799, version date July 2, 2026 (ONDANSETRON · Sportpharm LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • postoperative nausea and/or vomiting.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. (1.1) postoperative nausea and/or vomiting. (1.2) 1.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin.

Ondansetron Injection is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.

In patients in whom nausea and/or vomiting must be avoided postoperatively, Ondansetron Injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic Ondansetron Injection and experience nausea and/or vomiting postoperatively, Ondansetron Injection may be given to prevent further episodes.

Ondansetron Injection is approved for patients aged 1 month and older.

Contraindications

4 CONTRAINDICATIONS Ondansetron Injection is contraindicated for patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. Anaphylactic reactions have been reported in patients taking ondansetron [see Adverse Reactions (6.2)]. The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.

  • Patients known to have hypersensitivity (e.g., anaphylaxis) to this product or any of its components. (4)
  • Concomitant use of apomorphine. (4, 7.2)
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Cancer Chemotherapy (2.1):

  • Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients.
  • Adults and pediatric patients 6 months of age and older: The recommended dosage is 0.15 mg/kg per dose for 3 doses (maximum of 16 mg per dose), infused intravenously over 15 minutes.
  • Administer the first dose 30 minutes before the start of chemotherapy and subsequent doses 4 and 8 hours after the first dose. Prevention of Postoperative Nausea and/or Vomiting (2.2):
  • Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients.
  • See full prescribing information for the recommended dosage and administration instructions for adult and pediatric patients 1 month of age and older. Patients With Severe Hepatic Impairment (2.3):
  • Do not exceed a total daily dose of 8 mg.
2.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of…

2.1 Prevention of Nausea and Vomiting Associated With Initial and Repeat Courses of Emetogenic Chemotherapy Important Preparation Instructions

  • Dilution of Ondansetron Injection in 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection is required before administration to adult and pediatric patients for the prevention of nausea and vomiting associated with emetogenic chemotherapy. For pediatric patients between 6 months and 1 year of age and/or 10 kg or less: Depending on the fluid needs of the patient, Ondansetron Injection may be diluted in 10 to 50 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection.
  • Occasionally, ondansetron precipitates at the stopper/vial interface in vials stored upright. Potency and safety are not affected. If a precipitate is observed, resolubilize by shaking the vial vigorously.
  • Do not mix Ondansetron Injection with solutions for which physical and chemical compatibility has not been established. In particular, this applies to alkaline solutions as a precipitate may form.
  • Inspect the diluted Ondansetron Injection solution for particulate matter and discoloration before administration; discard if present.
  • Storage: After dilution, do not use beyond 24 hours. Although Ondansetron Injection is chemically and physically stable when diluted as recommended, sterile precautions should be observed because diluents generally do not contain preservative.
  • Compatibility: Ondansetron Injection is compatible and stable at room temperature under normal lighting conditions for 48 hours after dilution with the following intravenous fluids: 0.9% Sodium Chloride Injection, 5% Dextrose Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, and 3% Sodium Chloride Injection. Dosage and Administration The recommended dosage for adult and pediatric patients 6 months of age and older for prevention of nausea and vomiting associated with emetogenic chemotherapy is 0.15-mg/kg per dose for 3 doses (maximum of 16 mg per dose). Caution: Dilution of Ondansetron Injection is required in adult and pediatric patients prior to administration. Infuse intravenously over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy and then repeat 4 and 8 hours after the first dose.
2.2 Prevention of Postoperative Nausea

2.2 Prevention of Postoperative Nausea and/or Vomiting Important Preparation Instructions

  • Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients.
  • Inspect Ondansetron Injection visually for particulate matter and discoloration before administration; discard if present. Dosage and Administration The recommended dose and administration instructions for adult and pediatric patients 1 month of age and older for prevention of postoperative nausea and vomiting are shown in Table 1. Table 1. Recommended Dose and Administration of Ondansetron Injection for Prevention of Postoperative Nausea and/or Vomiting Population Recommended Single Dose Administration Instructions Timing of Administration Adults and pediatric patients older than 12 years of age 4 mg 1 May be administered intravenously or intramuscularly: Intravenously: infuse undiluted syringe contents (4 mg) over at least 30 seconds and preferably longer (over 2 to 5 minutes). Intramuscularly: inject undiluted syringe contents (4 mg) Administer immediately before induction of anesthesia, or postoperatively if the patient did not receive prophylactic antiemetics and experiences nausea and/or vomiting occurring within 2 hours after surgery 2,3 Pediatric patients 1 month to 12 years and more than 40 kg 4 mg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). Pediatric patients 1 month to 12 years and 40 kg or less 0.1 mg/kg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). 1. Few patients above 80 kg have been studied. 2. Administration of a second intravenous dose of 4 mg ondansetron postoperatively in adult patients who received a 4 mg prophylactic dose does not provide additional control of nausea and vomiting [see Clinical Studies (14.3)]. 3. For pediatric patients (1 month to 12 years) prevention of nausea and vomiting was only studied in patients who had not received prophylactic ondansetron.
2.3 Dosage Adjustment for Patients With Hepatic Impairment

2.3 Dosage Adjustment for Patients With Hepatic Impairment In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), a single maximal daily dose of 8 mg infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended. There is no experience beyond first-day administration of ondansetron in these patients [see Use in Specific Populations (8.6)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.7 Renal Impairment Although plasma clearance is reduced in patients with severe renal impairment (creatinine clearance < 30 mL/min), no dosage adjustment is recommended [see Clinical Pharmacology (12.3)].

Patients with Renal Impairment: Due to the very small contribution (5%) of renal clearance to the overall clearance, renal impairment was not expected to significantly influence the total clearance of ondansetron. However, ondansetron mean plasma clearance was reduced by about 41% in patients with severe renal impairment (creatinine clearance < 30 mL/min). This reduction in clearance is variable and was not consistent with an increase in half-life [see Use in Specific Populations (8.7)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life [see Clinical Pharmacology (12.3)]. In such patients, a total daily dose of 8 mg should not be exceeded [see Dosage and Administration (2.3)].

2.3 Dosage Adjustment for Patients With Hepatic Impairment In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), a single maximal daily dose of 8 mg infused over 15 minutes beginning 30 minutes before the start of the emetogenic chemotherapy is recommended. There is no experience beyond first-day administration of ondansetron in these patients [see Use in Specific Populations (8.6)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Little information is available about the use of ondansetron in pediatric surgical patients younger than 1 month [see Clinical Studies (14.2)]. Little information is available about the use of ondansetron in pediatric cancer patients younger than 6 months [see Clinical Studies (14.1), Dosage and Administration (2)].

The clearance of ondansetron in pediatric patients aged 1 month to 4 months is slower and the half-life is ~2.5-fold longer than patients who are aged > 4 to 24 months. As a precaution, it is recommended that patients younger than 4 months receiving this drug be closely monitored [see Clinical Pharmacology (12.3)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of subjects enrolled in cancer chemotherapy-induced and postoperative nausea and vomiting US- and foreign-controlled clinical trials, 862 were aged 65 years and older. No overall differences in safety or effectiveness were observed between subjects 65 years and older and younger subjects.

A reduction in clearance and increase in elimination half-life were seen in patients older than 75 years compared with younger subjects [see Clinical Pharmacology (12.3)]. There were an insufficient number of patients older than 75 years of age and older in the clinical trials to permit safety or efficacy conclusions in this age-group.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dosage adjustment is not needed in patients over the age of 65.

Administration

2.2 Prevention of Postoperative Nausea and/or Vomiting Important Preparation Instructions • Dilution of Ondansetron Injection is not required before administration to adult and pediatric patients. • Inspect Ondansetron Injection visually for particulate matter and discoloration before administration; discard if present. Dosage and Administration The recommended dose and administration instructions for adult and pediatric patients 1 month of age and older for prevention of postoperative nausea and vomiting are shown in Table 1. Table 1. Recommended Dose and Administration of Ondansetron Injection for Prevention of Postoperative Nausea and/or Vomiting Population Recommended Single Dose Administration Instructions Timing of Administration Adults and pediatric patients older than 12 years of age 4 mg 1 May be administered intravenously or intramuscularly: Intravenously: infuse undiluted syringe contents (4 mg) over at least 30 seconds and preferably longer (over 2 to 5 minutes). Intramuscularly: inject undiluted syringe contents (4 mg) Administer immediately before induction of anesthesia, or postoperatively if the patient did not receive prophylactic antiemetics and experiences nausea and/or vomiting occurring within 2 hours after surgery 2,3 Pediatric patients 1 month to 12 years and more than 40 kg 4 mg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). Pediatric patients 1 month to 12 years and 40 kg or less 0.1 mg/kg Infuse intravenously over at least 30 seconds and preferably longer (over 2 to 5 minutes). 1. Few patients above 80 kg have been studied. 2. Administration of a second intravenous dose of 4 mg ondansetron postoperatively in adult patients who received a 4 mg prophylactic dose does not provide additional control of nausea and vomiting [see Clinical Studies (14.3) ]. 3. For pediatric patients (1 month to 12 years) prevention of nausea and vomiting was only studied in patients who had not received prophylactic ondansetron.

US FDA label

Dosage forms

Philippines

  • ) solution for injection: 2 mg/mL (4 mg/2 mL, 2 mg/mL (8 mg/4 mL, 2 mg/mL (8 mg/4 mL) (4 mg/2 mL, 2 mg/mL(8 mg/4 mL, 250 mg/mL (500 mg/2 mL) (1 g/4 mL
  • Solution for injection: 2 mg/mL, 4 mg/mL
  • Film-coated tablet: 4 mg, 8 mg
  • Oral solution: 4 mg/5 mL
  • Orally disintegrating tablet: 8 mg
  • Solution for intravenous injection: 2 mg/mL
  • Syrup: 4 mg/5 mL
  • Tablet: 8 mg

Registered products in the Philippines

71 products registered with the Food and Drug Administration (FDA) Philippines list Ondansetron as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products71
Philippine FDA-registered products for Ondansetron
Package insert
AmnosetOndansetron
2mg/ml Solution For Injection (IM/IV)4 mL USP Type I Clear and Colorless Glass Ampoule of 5's)
RxVAT-exempt
Bharat Parenterals LimitedIndia
Biocare Lifesciences Inc.Trader: AMN Life Science Pvt. Ltd.
DRP-4069
Oct 19, 2027
AsetronOndansetron (as hydrochloride)
2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2 mL USP Type I Amber Glass Ampoule (Box of 5's)
RxVAT-exempt
Scott-Edil Pharmacia LimitedIndia
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-4089-02
Nov 8, 2027
Beludan-2Ondansetron (as hydrochloride)
2 mg/mL Solution For Injection (IM/IV)Type I clear glass ampoule x 1 mL (Box of 10's)
RxVAT-exempt
Hiral Labs LimitedIndia
Bellus Life Solutions, Inc.
DRP-12911
Oct 25, 2027
Beludan-4Ondansetron hydrochloride
4 mg/mL Solution for Injection (I.M./I.V.)Type I clear glass ampoule x 1mL (Box of 10's)
RxVAT-exempt
Hiral Labs LimitedIndia
Bellus Life Solutions, Inc.
DRP-15883
Sep 25, 2029
DanasetOndansetron (as Hydrochloride)
2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) (Box of 5’s)
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-5894-04
Dec 11, 2029
EgezetOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 100's)
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Pharma 518, Inc.Importer: Ambica International Corporation
DRP-6106-01
Apr 8, 2030
EgezetOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Pharma 518, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609-04
Apr 16, 2037
EmistopOndansetron
2 mg/mL Solution for Intravenous InjectionGlass ampoule in open tray x 4 mL (Box of 5's, 10's and 25's)
RxVAT-exempt
Baxter Pharmaceuticals India Private LimitedIndia
Macropharma CorporationImporter: Baxter Healthcare Philippines Inc.
DRP-6600
Jul 8, 2030
EmitronOndansetron (As Hydrochloride)
2mg/mL (8mg/4mL) Solution For Injection (Im/Iv)USP Type I clear and colorless glass ampoule x 4 mL(Box of 5 's) and x 2 mL (Box of 10's)
RxVAT-exempt
Cisen Pharmaceutical Co., Ltd.China
ENDURE MEDICAL, INC.
DRP-7505
Oct 15, 2031
EmodanOndansetron (as hydrochloride)
250 mg/mL (500 mg/2 mL) (1 g/4 mL) Solution for Injection (I.M./I.V.)USP Type I Colorless Glass Ampoule x 4 mL (Box of 5's)
RxVAT-exempt
Korea United Pharm. Inc.Korea
Qualimed Pharma Inc.
DR-XY29866
Jul 4, 2030
Enset-4Ondansetron (as hydrochloride dihydrate)
4 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100 tablets)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International CorporationTrader: Endurance Healthcare Ltd.
DRP-6608
Mar 30, 2031
ENSET-8Ondansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 10's, 30's and 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609
Mar 30, 2037
FrenvoOndansetron (as hydrochloride dihydrate)
4 mg/5 mL Syrup0 mL capacity (50 mL net content) Ph. Eur. Type III glass bottle with white polypropylene/polyethylene cap and with a dosing device of 2.5 mL 5 mL double ended spoon (Box of 1's)
RxVAT-exempt
Delpharm Bladel B.V.Netherlands
Ambica International Corporation
DR-XY48494
Nov 25, 2027
KodasetronOndansetron (as hydrochloride dihydrate)
2 mg/mL Solution for Injection (I.V./I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's)
RxVAT-exempt
Pt. Novell Pharmaceutical LaboaratoriesIndonesia
Kodapharm Med Corp.Importer: Accesspoint International Trading Inc.
DRP-13194-02
Dec 22, 2027
NausanOndansetron (as Hydrochloride)
2 mg/mL (4 mg / 2 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 2 mL (Box of 5's).
RxVAT-exempt
Swiss Parenterals Ltd. (Block-B)India
Despina Pharma Inc.
DRP-13339
Feb 1, 2028
NauventOndansetron (as hydrochloride)
2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2mL USP Type I Amber Glass Ampoule (Box of 5's)
RxVAT-exempt
Scott-Edil Pharmacia LimitedIndia
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-4089-03
Nov 8, 2027
NauzexOndansetron (as hydrochloride)
2 mg/mL (8 mg/4 mL) Solution for Injection (IM/IV)Type I Amber Colored Glass Ampoule x 5 mL (Net content: 4 mL) (Box of 1's)
RxVAT-exempt
Aroma İlaç San. Ltd. ŞtiTurkey
Importer: Medinova Pharmaceutical, Inc.
DRP-10891
Dec 14, 2026
NitronOndansetron Hydrochloride
2 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 2 mL (Box of 5's)
RxVAT-exempt
Nitin Lifesciences Ltd.India
Seapharma International, Inc.
DRP-4945
Nov 22, 2028
NoneOndansetron (as hydrochloride dihydrate)
2 mg / mL Solution for Injection (I.V/I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's)
RxVAT-exempt
PT. Novell Pharmaceutical LaboratoriesIndonesia
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-13194-03
Dec 22, 2027
NuovomedOndansetron (as hydrochloride dihydrate)
2mg/mL (8 mg/4 mL) Solution For Injection (IM/IV)5-mL capacity Type -I Clear Glass Ampoule in Plastic Tray x 4 mL (net content) (Box of 10's)
RxVAT-exempt
Skymap Pharmaceuticals Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-18759
Sep 1, 2032
Odanson-8Ondansetron
8mg Orally Disintegrating TabletAlu/Alu Blister Pack x 10's (Box of 30's).
RxVAT-exempt
Unison Pharmaceuticals Pvt. Ltd.India
Macropharma Corporation
DRP-13430
Feb 16, 2028
OndacareOndansetron (as hydrochloride dihydrate)
2 mg/mL Solution For Injection (IM/IV)Type I Clear Glass Ampoule in PVC Trya x 4 mL (Box of 10's)
RxVAT-exempt
Able Medical Company LimitedThailand
Euro-Care Products Philippines
DRP-18758
Sep 1, 2031
OndaneoOndansetron
2mg/mL (4mg/2mL) Solution for Injection (IM/IV)LDPE Ampoule x 2 mL in Aluminum Pouch x 5's (Box of 10's)
RxVAT-exempt
Aculife Healthcare Private LimitedIndia
Blue Global (FZE)
DRP-18036
Apr 28, 2032
Ondansaph-8Ondansetron (As Hydrochloride)
2mg/mL(8mg/4mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule in PVC Tray x 4 mL (Box of 5's, 10's and 25's)
RxVAT-exempt
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11549
Mar 30, 2027
OndaSaveOndansetron (as hydrochloride dihydrate)
2 mg / mL Solution for Injection (I.V./I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's)
RxVAT-exempt
Pt. Novell Pharmaceutical LaboratoriesIndonesia
Savelink Pharma and Trading Co.Importer: Accesspoint International Trading, Inc.
DRP-13194-04
Dec 22, 2027
OndatrixOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
D&G PharmaImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609-01
Apr 16, 2037
OndavellOndansetron (as hydrochloride dihydrate)
2 mg/mL (8 mg/4 mL) Solution for Injection (I.M./I.V.)4 mL Type I Clear and Colorless Glass Ampoule (Box of 5's in Clear PVC Tray)
RxVAT-exempt
PT Novell Pharmaceutical LaboratoriesIndonesia
PROSWEAL HEALTHCARE INC.
DR-XY43655
Aug 22, 2029
OndavellOndansetron (as hydrochloride dihydrate)
2mg/mL (4mg/2mL) Solution for Injection (I.M./I.V.)2 mL Type I clear and colorless glass ampoule (Box of 5's in clear PVC tray)
RxVAT-exempt
PT Novell Pharmaceutical LaboratoriesIndonesia
PROSWEAL HEALTHCARE INC.
DR-XY43611
Aug 11, 2029
OndavellOndansetron (as hydrochloride)
4 mg Film-Coated TabletAluminum Foil Strip x 6 Tablets (Box of 12's)
RxVAT-exempt
PT Novell Pharmaceutical LaboratoriesIndonesia
PROSWEAL HEALTHCARE INC.
DR-XY43610
Aug 11, 2029
OndavellOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletBox 2 Aluminum Foil Strips x 6's
RxVAT-exempt
PT Novell Pharmaceutical LaboratoriesIndonesia
Prosweal Healthcare Inc.
DR-XY45022
Feb 2, 2031
OndavidOndansetron (as hydrochloride)
2 mg/mL Solution for Injection (IM/IV)Borosilicate Glass Ampoule in PVC tray x 2 mL (Box of 5's ); Borosilicate Glass Ampoule in PVC tray x 4 mL (Box of 5's)
RxVAT-exempt
Qilu Pharmaceutical, Co., Ltd.China
Hovid Inc.Trader: Hovid Bhd.
DR-XY46599
Jun 14, 2029
OndengetOndansetron (as Hydrochloride)
2 mg/mL Solution for Injection (IM/IV)Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) (Box of 5’s)
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
2MG IncorporatedImporter: Ambica International Corporation
DRP-5894-03
Dec 11, 2029
OndensOndansetron (as Hydrochloride)
2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Colour Band x 5 mL (4 mL net volume) (Box of 5's)
RxVAT-exempt
Cadilla Pharmaceuticals Ltd.India
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-5894-06
Dec 11, 2029
OndensOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Detoxicare Phils., Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609-07
Apr 16, 2037
OnderoOndansetron (as hydrochloride dihydrate)
2 mg/mL Solution for Injection (I.M./I.V.)2 mL-net content USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper and light blue aluminum seal with light blue PP flip-off cap (Box of 1's)
RxVAT-exempt
Aspiro Pharma LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-14802
Jan 11, 2029
OndiOndansetron (as hydrochloride)
2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)Clear Glass Ampoule x 2 mL and 4 mL (Box of 10 's)
RxVAT-exempt
Sakar Healthcare Pvt. Ltd.India
Macropharma Corporation
DRP-10895
Dec 14, 2031
Onetic 8Ondansetron (As Hydrochloride Dihydrate)
2 mg/mL (8 mg/4 mL) Solution for Injection (I.M./I.V.)Type I clear, colorless glass ampoule x 4 mL (Box of 5's)
RxVAT-exempt
PT Pratapa NirmalaIndonesia
Importer: Exa Life Care Pharma, Inc.
DRP-11994
May 27, 2027
Onetic® 4Ondansetron (as hydrochloride dihydrate)
2 mg/mL (4 mg/2 mL) Solution For Injection (I.M./I.V.)Clear, Colorless Type I Borosilicate Glass Ampoule x 2mL (Box of 5's)
RxVAT-exempt
PT. Pratapa NirmalaIndonesia
Importer: Exa Life Care Pharma Inc.
DRP-11342
Mar 4, 2027
Onriv 8Ondansetron (as Hydrochloride)
2 mg/mL (8 mg/4 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 4 mL in a PVC plastic tray (Box of 5’s)
RxVAT-exempt
East African (India) OverseasIndia
Ambica International Corporation
DRP-18812
Sep 16, 2031
OnsetraOndansetron (as hydrochloride dihydrate)
2 mg/mL (8 mg/4 mL) Solution For Injection (IM/IV)5 mL-capacity Clear Glass Ampoule x 4 mL net content in Plastic Tray (Box of 10's)
RxVAT-exempt
Hana Pharm. Co., Ltd.South Korea
JLT Pharma Inc.
DRP-18607
Aug 5, 2031
OnsetronOndansetron
2 mg/mL Solution for InjectionUSP Type I Clear Glass Ampoule x 2 mL (Box of 1's); USP Type I Clear Glass Ampoule x 4 mL (Box of 1's)
RxVAT-exempt
Zee Laboratories LimitedIndia
Eon Pharmatek, Inc
DR-XY42391
Jul 4, 2030
OnsettOndansetron (as Hydrochloride)
2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Colour Band x 2 mL (2 mL net volume) (Box of 5’s); Flint USP Type I Glass Ampoule with Blue Colour Band x 5 mL (4 mL net volume) (Box of 5’s)
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Caledan Pharma Corp.Importer: Ambica International Corporation
DRP-5894
Dec 11, 2029
Onsett 4Ondansetron (as hydrochloride dihydrate)
4 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s and 100's)
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Ambica International Corporation
DRP-6105
Apr 8, 2030
Onsett 8Ondansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 10’s; Alu/Alu Blister Pack x 10’s Box of 100’s
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Genace Pharma DistributorImporter: Ambica International Corporation
DRP-6106
Apr 8, 2030
OnsiaOndansetron (As Hydrochloride Dihydrate)
2 mg/mL (4 mg/2 mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 2 mL
RxVAT-exempt
Siam Bheasach Co., Ltd.Thailand
MG Prime Pharmaceutical, Inc.Importer: Atlantic Pharmaceuticals, Inc.
DR-XY42169
Aug 11, 2031
OnsiaOndansetron (as Hydrochloride Dihydrate)
2 mg/mL (8 mg/4 mL) Solution for Injection (I.V.)USP Type I Clear Glass Ampoule x 4 mL (Box of 5's)
RxVAT-exempt
SIAM BHEASACH CO., LTD.Thailand
MG PRIME PHARMACEUTICAL, INC.Importer: Atlantic Pharmaceuticals, Inc.
DR-XY42426
Aug 16, 2028
OnsiatabOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
MG Prime Pharmaceutical, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609-05
Jul 31, 2037
Onstal-ForteOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
SGS Healthcare Co.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609-02
Apr 26, 2037
OnTheGet 4Ondansetron (as hydrochloride dihydrate)
2 mg/mL (4 mg/ 2 mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule in White Tray x 2 mL (Box of 5's)
RxVAT-exempt
Eva Pharma for Pharmaceuticals Appliances and MedicalEgypt
Getmeds Philippines Inc.
DRP-17961
Apr 15, 2031
OnzetOndansetron (as Hydrochloride Dihydrate)
2 mg/mL (8 mg/4 mL) Solution for Injection (IM/IV)5 mL-Capacity, 4 mL-net content Type I Clear and Colorless Glass Ampoule (Box of 10's)
RxVAT-exempt
Taiwan Biotech Co., Ltd.China
The Cathay Drug Co., Inc.
DR-XY45574
Aug 24, 2031
OnzetOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 10's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609-03
Apr 16, 2037
OtronOndansetron (as Hydrochloride Dihydrate)
2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 2 mL (Box of 10's)
RxVAT-exempt
Myungmoon Pharmaceutical Co., Ltd.Korea
Marcburg Philippines Inc.
DR-XY44009
Dec 18, 2029
OtronOndansetron (as hydrochloride dihydrate)
2 mg/mL (8 mg/4 mL) Solution for Injection (IM/IV)USP Type I Glass Ampoule x 4 mL (Box of 10's)
RxVAT-exempt
Myungmoon Pharmaceutical Co., Ltd.Korea
Marcburg Philippines Inc.
DR-XY44675
Feb 15, 2031
OtrosiaOndansetron (as hydrochloride)
2 mg/mL (8 mg/4 mL) Solution For Injection (Iv/Im)Type I clear glass ampoule x 4 mL (Box of 10’s)
RxVAT-exempt
Scott-Edil Pharmacia Ltd.,India
Despina Pharma Inc.
DRP-18034
Apr 28, 2031
PhiltronOndansetron (as hydrochloride dihydrate)
2 mg/mL Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 2 mL in a plastic tray (Box of 5's)
RxVAT-exempt
Ratnaris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-17555
Jan 26, 2031
RasetronOndansetron (as hydrochloride)
2 mg/mL Solution for Injection (IM/IV)USP Type I clear glass ampoule x 2 mL and 4 mL (Box of 5's and 10's)
RxVAT-exempt
Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China
Raquel Abbas Pharma Inc.
DRP-17848
Mar 23, 2031
SaphdosetronOndansetron (As Hydrochloride)
2mg/ml (8mg/4ml) (4mg/2ml) Solution For Injection (IM/IV)Type I Clear Glass Ampoule in PVC Tray x 2 mL and 4 mL (Box of 5's, 10's and 25's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-12506
Aug 22, 2027
SavetronOndansetron (as Hydrochloride)
2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Colour Band x 2 mL (2 mL net volume) (Box of 5's); Flint USP Type I Glass Ampoule with Blue Colour Band x 5 mL (4 mL net volume) (Box of 5's)
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Curasave PharmaImporter: Ambica International Corporation
DRP-5894-05
Dec 11, 2029
StrobonOndansetron (as hydrochloride dihydrate)
4mg / 5 mL Oral SolutionType III amber glass bottle (with measuring cup) x 60 mL (box of 1's)
RxVAT-exempt
Limited Liability Company "Kusum Pharm"Ukraine
Kusum Healthcare Private Limited Branch Office
DR-XY48968
Dec 28, 2028
TrinsetronOndansetron (as Hydrochloride)
2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) Box of 5’s
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Genace Pharma DistributorImporter: Ambica International Corporation
DRP-5894-01
Dec 11, 2029
TroysetronOndansetron (as hydrochloride)
2mg/mL Solution for Injection (IM/IV)Type I Clear Flint Glass Ampoule with Yellow OPC and Ring x 2mL (Box of 5's) Type I Clear Flint Glass Ampoule with Pink OPC and Ring x 4mL (Box of 5's)
RxVAT-exempt
Troikaa Pharmaceuticals LimitedIndia
Troikaa Pharmaceuticals Philippines, Inc.
DRP-16319
Feb 4, 2030
VominoOndansetron (as hydrochloride)
2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2ml USP Type I Amber Glass Ampoule (Box of 5's)
RxVAT-exempt
Scott-Edil Pharmacia LimitedIndia
Curasave PharmaImporter: Pharmakon Biotec Inc.
DRP-4089
Nov 8, 2027
VomistatOndansetron (as hydrochloride)
2 mg / mL (8 mg / 4 mL) Solution for Injection (IM/IV)Type I Amber Colored Glass Ampoule x 5 mL (Net content: 4 mL) (Box of 1's)
RxVAT-exempt
Aroma Ilac San. Ltd. StiTurkey
Macropharma CorporationImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San. Ve Tic. A.S.
DRP-10891-01
Dec 14, 2026
VomistopOndansetron (as hydrochloride dihydrate)
2 mg / mL Solution for Injection (I.V/I.M.)Type I clear and colorless glass ampoule x 2 mL and 4 mL (Box of 5's)
RxVAT-exempt
PT. Novell Pharmaceutical LaboratoriesIndonesia
Euro-Care Products PhilippinesImporter: Accesspoint International Trading Inc.
DRP-13194-01
Dec 22, 2027
Vomiz 8Ondansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 10's and 100's)
RxVAT-exempt
Zydus Lifesciences LimitedIndia
Macropharma Corporation
DRP-7286
Mar 6, 2031
Z-TronOndansetron (as hydrochloride)
2 mg/mL (4 mg/2 mL) Solution for Injection (IM/IV)2ml USP Type I Amber Glass Ampoule (Box of 5's)
RxVAT-exempt
Scott-Edil Pharmacia LimitedIndia
Genace Pharma DistributorImporter: Pharmakon Biotec Inc.
DRP-4089-01
Nov 8, 2027
ZetronOndansetron (as hydrochloride)
8mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Corona Remedies Private LimitedIndia
Biocare Lifesciences, Inc.
DRP-12060
Jun 7, 2027
ZofranOndansetron (as Hydrochloride dihydrate)
2 mg/mL Solution for Injection (I.M./I.V.)Clear Glass Ampoule x 2 mL (Box of 10's); Clear Glass Ampoule x 4 mL (Box of 8's)
RxVAT-exempt
Delpharm Boucherville Canada Inc.Canada
Importer: Sandoz Philippines Corporation
DR-XY13358
Jul 21, 2030
ZofranOndansetron (as hydrochloride dihydrate)
8 mg TabletAlu/Alu Blister Pack x 5’s Box of 10's
RxVAT-exempt
Aspen Bad Oldesloe GmbHGermany
Importer: Novartis Healthcare Philippines, Inc.
DR-XY13371
Oct 15, 2027
ZukastopOndansetron (as Hydrochloride)
2 mg/mL Solution for Injection (I.M./I.V.)Flint USP Type I Glass Ampoule with Blue Color Band x 2 mL (2 mL net volume) (Box of 5’s); Flint USP Type I Glass Ampoule with Blue Color Band x 5 mL (4 mL net volume) (Box of 5’s)
RxVAT-exempt
Cadila Pharmaceuticals Ltd.India
Ellebasy Medicale Group Inc.Importer: Ambica International Corporation
DRP-5894-02
Dec 11, 2029
ZukastopOndansetron (as hydrochloride dihydrate)
8 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ellebasy Medicale Group Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6609-06
Apr 26, 2037

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Ondansetron Injection, USP: 4 mg/2 mL clear, colorless, nonpyrogenic, sterile solution in a single-dose vial. Injection: 4 mg/2 mL single-dose vial. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and bronchospasm have been reported in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists. (5.1)
  • QT Prolongation and Torsade de Pointes: QT prolongation occurs in a dose-dependent manner. Cases of Torsade de Pointes have been reported. Avoid Ondansetron Injection in patients with congenital long QT syndrome. (5.2)
  • Serotonin Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor agonists alone but particularly with concomitant use of serotonergic drugs. (5.3)
  • Myocardial Ischemia: Do not exceed the recommended infusion rate and monitor patients during and after administration. (2.1, 2.2, 5.4)
  • Masking of Progressive Ileus and/or Gastric Distension Following Abdominal Surgery or Chemotherapy-Induced Nausea and Vomiting: Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. (5.5)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists.

5.2 QT Prolongation

5.2 QT Prolongation Ondansetron prolongs the QT interval in a dose-dependent manner [see Clinical Pharmacology (12.2)]. In addition, postmarketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid Ondansetron Injection in patients with congenital long QT syndrome. Electrocardiogram (ECG) monitoring is recommended in patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or patients taking other medicinal products that lead to QT prolongation.

5.3 Serotonin Syndrome

5.3 Serotonin Syndrome The development of serotonin syndrome has been reported with 5-HT 3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).

Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of Ondansetron Injection alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT 3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue Ondansetron Injection and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if Ondansetron Injection is used concomitantly with other serotonergic drugs [see Drug Interactions (7.5), Overdosage (10)].

5.4 Myocardial Ischemia

5.4 Myocardial Ischemia Myocardial ischemia has been reported in patients treated with ondansetron. In some cases, predominantly during intravenous administration, the symptoms appeared immediately after administration but resolved with prompt treatment. Coronary artery spasm appears to be the most common underlying cause.

Therefore, do not exceed the recommended infusion rate of Ondansetron Injection and monitor patients for signs and symptoms of myocardial ischemia during and after administration [see Dosage and Administration (2.1, 2.2) and Adverse Reactions (6.2)].

5.5 Masking of Progressive Ileus and Gastric Distension

5.5 Masking of Progressive Ileus and Gastric Distension The use of Ondansetron Injection in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and gastric distension. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.

Ondansetron Injection is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction.

Drug interactions

Drug interactions (US label) US FDA label
7.1 Drugs Affecting Cytochrome P-450 Enzymes

7.1 Drugs Affecting Cytochrome P-450 Enzymes Ondansetron does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron [see Clinical Pharmacology (12.3)].

On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.

7.2 Apomorphine

7.2 Apomorphine Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with ondansetron is contraindicated [see Contraindications (4)].

7.3 Phenytoin, Carbamazepine, and Rifampin

7.3 Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs [see Clinical Pharmacology (12.3)].

7.4 Tramadol

7.4 Tramadol Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small trials indicate that concomitant use of ondansetron may result in reduced analgesic activity of tramadol. Patients on concomitant ondansetron self-administered tramadol more frequently in these trials, leading to an increased cumulative dose in patient-controlled administration of tramadol.

7.5 Serotonergic Drugs

7.5 Serotonergic Drugs Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT 3 receptor antagonists and other serotonergic drugs, including SSRIs and SNRIs [see Warnings and Precautions (5.3)].

7.6 Chemotherapy

7.6 Chemotherapy In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron. In a crossover trial in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate.

7.7 Temazepam

7.7 Temazepam The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.

7.8 Alfentanil and Atracurium

7.8 Alfentanil and Atracurium Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. Interactions with general or local anesthetics have not been studied.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro metabolism studies have shown that ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4.

In terms of overall ondansetron turnover, CYP3A4 plays a predominant role while formation of the major in vivo metabolites is apparently mediated by CYP1A2.

The role of CYP2D6 in ondansetron in vivo metabolism is relatively minor.

The pharmacokinetics of intravenous ondansetron did not differ between subjects who were poor metabolizers of CYP2D6 and those who were extensive metabolizers of CYP2D6, further supporting the limited role of CYP2D6 in ondansetron disposition in vivo .

Drug Interaction Studies CYP 3A4 Inducers : Ondansetron elimination may be affected by cytochrome P-450 inducers.

In a pharmacokinetic trial of 16 epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin, a reduction in AUC, C max , and t ½ of ondansetron was observed.

These changes in ondansetron exposure with CYP3A4 inducers are not thought to be clinically relevant [see Drug Interactions (7.3) ] .

Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron [see Clinical Pharmacology (12.3) ] .

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] QT Prolongation [see Warnings and Precautions (5.2)] Serotonin Syndrome [see Warnings and Precautions (5.3)] Myocardial Ischemia [see Warnings and Precautions (5.4)] Masking of Progressive Ileus and Gastric Distension [see Warnings and Precautions (5.5)] Chemotherapy-Induced Nausea and Vomiting: · The most common adverse reactions (≥7%) in adults are diarrhea, headache, and fever. (6.1)
  • Postoperative Nausea and Vomiting: · The most common adverse reaction (≥10%) which occurs at a higher frequency compared with placebo in adults is headache. (6.1)
  • · The most common adverse reaction (≥2%) which occurs at a higher frequency compared with placebo in pediatric patients aged 1 to 24 months is diarrhea. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The following adverse reactions have been reported in clinical trials of adult patients treated with ondansetron, the active ingredient of intravenous Ondansetron Injection across a range of dosages.

A causal relationship to therapy with Ondansetron Injection was unclear in many cases. Chemotherapy-Induced Nausea and Vomiting Table 2. Adverse Reactions Reported in > 5% of Adult Patients Who Received Ondansetron at a Dosage of Three 0.15-mg/kg Doses Adverse Reaction Number of Adult Patients With Reaction Ondansetron Injection 0.15 mg/kg x 3 (n = 419) Metoclopramide (n = 156) Placebo (n = 34) Diarrhea 16% 44% 18% Headache 17% 7% 15% Fever 8% 5% 3% Cardiovascular: Rare cases of angina (chest pain), electrocardiographic alterations, hypotension, and tachycardia have been reported.

Gastrointestinal: Constipation has been reported in 11% of chemotherapy patients receiving multiday ondansetron. Hepatic: In comparative trials in cisplatin chemotherapy patients with normal baseline values of aspartate transaminase (AST) and alanine transaminase (ALT), these enzymes have been reported to exceed twice the upper limit of normal in approximately 5% of patients.

The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic hepatic disease did not occur. Integumentary: Rash has occurred in approximately 1% of patients receiving ondansetron.

Neurological: There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving Ondansetron Injection, and rare cases of grand mal seizure. Other: Rare cases of hypokalemia have been reported. Postoperative Nausea and/or Vomiting The adverse reactions in Table 3 have been reported in ≥ 2% of adults receiving ondansetron at a dosage of 4 mg intravenous over 2 to 5 minutes in clinical trials.

Table 3. Adverse Reactions Reported in ≥ 2% (and with greater frequency than the placebo group) of Adult Patients Receiving Ondansetron at a Dosage of 4 mg Intravenous Over 2 to 5 Minutes Adverse Reaction 1,2 Ondansetron Injection 4 mg Intravenous (n = 547) Placebo (n = 547) Headache 92 (17%) 77 (14%) Drowsiness/Sedation 44 (8%) 37 (7%) Injection-site reaction 21 (4%) 18 (3%) Fever 10 (2%) 6 (1%) Cold sensation 9 (2%) 8 (1%) Pruritus 9 (2%) 3 (< 1%) Paresthesia 9 (2%) 2 (< 1%) 1.

Adverse reactions: Rates of these reactions were not significantly different in the ondansetron and placebo groups. 2. Patients were receiving multiple concomitant perioperative and postoperative medications. Pediatric Use: Rates of adverse reactions were similar in both the ondansetron and placebo groups in pediatric patients receiving ondansetron (a single 0.1-mg/kg dose for pediatric patients weighing 40 kg or less, or 4 mg for pediatric patients weighing more than 40 kg) administered intravenously over at least 30 seconds.

Diarrhea was seen more frequently in patients taking Ondansetron Injection (2%) compared with placebo (< 1%) in the 1-month to 24-month age-group. These patients were receiving multiple concomitant perioperative and postoperative medications.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ondansetron. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron. Cardiovascular Arrhythmias (including ventricular and supraventricular tachycardia, premature ventricular contractions, and atrial fibrillation), bradycardia, electrocardiographic alterations (including second-degree heart block, QT/QTc interval prolongation, and ST segment depression), palpitations, and syncope.

Rarely and predominantly with intravenous ondansetron, transient ECG changes, including QT/QTc interval prolongation have been reported [see Warnings and Precautions (5.2)]. Myocardial ischemia was reported predominately with intravenous administration [see Warnings and Precautions (5.4)]. General Flushing: Rare cases of hypersensitivity reactions, sometimes severe (e.g., anaphylactic reactions, angioedema, bronchospasm, cardiopulmonary arrest, hypotension, laryngeal edema, laryngospasm, shock, shortness of breath, stridor) have also been reported.

A positive lymphocyte transformation test to ondansetron has been reported, which suggests immunologic sensitivity to ondansetron. Hepatobiliary Liver enzyme abnormalities have been reported. Liver failure and death have been reported in patients with cancer receiving concurrent medications, including potentially hepatotoxic cytotoxic chemotherapy and antibiotics.

Local Reactions Pain, redness, and burning at site of injection. Lower Respiratory Hiccups. Neurological Oculogyric crisis, appearing alone, as well as with other dystonic reactions. Transient dizziness during or shortly after intravenous infusion. Skin Urticaria, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Eye Disorders Cases of transient blindness, predominantly during intravenous administration, have been reported.

These cases of transient blindness were reported to resolve within a few minutes up to 48 hours. Transient blurred vision, in some cases associated with abnormalities of accommodation, has also been reported.

Adverse reaction frequency tables (US label) US FDA label
Adverse Reaction Number of Adult Patients With Reaction
Ondansetron Injection 0.15 mg/kg x 3 (n = 419) Metoclopramide (n = 156) Placebo (n = 34)
Diarrhea16%44%18%
Headache17%7%15%
Fever8%5%3%
Adverse Reaction1,2 Ondansetron Injection 4 mg Intravenous (n = 547) Placebo (n = 547)
Headache 92 (17%) 77 (14%)
Drowsiness/Sedation 44 (8%) 37 (7%)
Injection-site reaction 21 (4%) 18 (3%)
Fever 10 (2%) 6 (1%)
Cold sensation 9 (2%) 8 (1%)
Pruritus 9 (2%) 3 (< 1%)
Paresthesia 9 (2%) 2 (< 1%)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Published epidemiological studies on the association between ondansetron use and major birth defects have reported inconsistent findings and have important methodological limitations that preclude conclusions about the safety of ondansetron use in pregnancy (see Data). Available postmarketing data have not identified a drug-associated risk of miscarriage or adverse maternal outcomes.

Reproductive studies in rats and rabbits did not show evidence of harm to the fetus when ondansetron was administered intravenously during organogenesis at approximately 3.6 and 2.9 times the maximum recommended human intravenous dose of 0.15 mg/kg given three times a day, based on body surface area (BSA), respectively (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, miscarriages, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Available data on ondansetron use in pregnant women from several published epidemiological studies preclude an assessment of a drug-associated risk of adverse fetal outcomes due to important methodological limitations, including the uncertainty of whether women who filled a prescription actually took the medication, the concomitant use of other medications or treatments, recall bias, and other unadjusted confounders.

Ondansetron exposure in utero has not been associated with overall major congenital malformations in aggregate analyses. One large retrospective cohort study examined 1970 women who received a prescription for ondansetron during pregnancy and reported no association between ondansetron exposure and major congenital malformations, miscarriage, stillbirth, preterm delivery, infants of low birth weight, or infants small for gestational age.

Two large retrospective cohort studies and one case-control study have assessed ondansetron exposure in the first trimester and risk of cardiovascular defects with inconsistent findings. Relative risks (RR) ranged from 0.97 (95% CI 0.86 to 1.10) to 1.62 (95% CI 1.04, 2.54). A subset analysis in one of the cohort studies observed that ondansetron was specifically associated with cardiac septal defects (RR 2.05, 95% CI 1.19, 3.28); however this association was not confirmed in other studies.

Several studies have assessed ondansetron and the risk of oral clefts with inconsistent findings. A retrospective cohort study of 1.8 million pregnancies in the US Medicaid Database showed an increased risk of oral clefts among 88,467 pregnancies in which oral ondansetron was prescribed in the first trimester (RR 1.24, 95% CI 1.03, 1.48), but no such association was reported with intravenous ondansetron in 23,866 pregnancies (RR 0.95, 95% CI 0.63, 1.43).

In the subgroup of women who received both forms of administration, the RR was 1.07 (95% CI 0.59, 1.93). Two case-control studies, using data from birth defects surveillance programs, reported conflicting associations between maternal use of ondansetron and isolated cleft palate (OR 1.6 [95% CI 1.1, 2.3] and 0.5 [95% CI 0.3, 1.0]).

It is unknown whether ondansetron exposure in utero in the cases of cleft palate occurred during the time of palate formation (the palate is formed between the 6th and 9th weeks of pregnancy). Animal Data In embryo-fetal development studies in rats and rabbits, pregnant animals received intravenous doses of ondansetron up to 10 mg/kg/day and 4 mg/kg/day, respectively, during the period of organogenesis.

With the exception of short periods of maternal weight loss and a slight increase in the incidence of early uterine deaths at the high dose level in rabbits, there were no significant effects of ondansetron on the maternal animals or the development of the offspring. At doses of 10 mg/kg/day in rats and 4 mg/kg/day in rabbits, the maternal exposure margin was approximately 3.6 and 2.9 times the maximum recommended human oral dose of 0.15 mg/kg given three times a day, respectively, based on BSA.

No intravenous pre- and post-natal developmental toxicity study was performed with ondansetron. In an oral pre- and post-natal development study pregnant rats received oral doses of ondansetron up to 15 mg/kg/day from Day 17 of pregnancy to litter Day 21. With the exception of a slight reduction in maternal body weight gain, there were no effects upon the pregnant rats and the pre- and postnatal development of their offspring, including reproductive performance of the mated F1 generation.

Mechanism of action

12.1 Mechanism of Action Ondansetron is a selective 5-HT 3 receptor antagonist. While ondansetron’s mechanism of action has not been fully characterized, it is not a dopamine-receptor antagonist.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time. In another trial in 6 normal male volunteers, a 16 mg dose infused over 5 minutes showed no effect of the drug on cardiac output, heart rate, stroke volume, blood pressure, or ECG.

Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers. Ondansetron has no effect on plasma prolactin concentrations. In a gender balanced pharmacodynamic trial (n = 56), ondansetron 4 mg administered intravenously or intramuscularly was dynamically similar in the prevention of nausea and vomiting using the ipecacuanha model of emesis.

Cardiac Electrophysiology QTc interval prolongation was studied in a double-blind, single intravenous dose, placebo- and positive-controlled, crossover trial in 58 healthy subjects. The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline correction was 19.5 (21.8) ms and 5.6 (7.4) ms after 15-minute intravenous infusions of 32 mg and 8 mg Ondansetron Injection, respectively.

A significant exposure-response relationship was identified between ondansetron concentration and ΔΔQTcF. Using the established exposure-response relationship, 24 mg infused intravenously over 15 minutes had a mean predicted (95% upper prediction interval) ΔΔQTcF of 14.0 (16.3) ms. In contrast, 16 mg infused intravenously over 15 minutes using the same model had a mean predicted (95% upper prediction interval) ΔΔQTcF of 9.1 (11.2) ms.

In this study, the 8-mg dose infused over 15 minutes did not prolong the QT interval to any clinically relevant extent.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Pharmacokinetics in Normal Adult Volunteers Age-group (years) n Peak Plasma Concentration (ng/mL) Mean Elimination Half-life (h) Plasma Clearance (L/h/kg) 19-40 11 102 3.5 0.381 61-74 12 106 4.7 0.319 ≥ 75 11 170 5.5 0.262 Absorption A trial was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics of a single 4-mg dose administered as a 5-minute infusion compared with a single intramuscular injection.

Excretion : In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.

Specific Populations Geriatric Patients : A reduction in clearance and increase in elimination half-life are seen in patients older than 75 years of age [see Use in Specific Populations (8.5) ] .

Pharmacokinetics in Pediatric Cancer Patients Aged 1 Month to 18 Years Subjects and Age-group N CL (L/h/kg) Vd ss (L/kg) t ½ (h) Geometric Mean Mean Pediatric Cancer Patients 4 to 18 years N = 21 0.599 1.9 2.8 Population PK Patients 1 1 month to 48 months N = 115 0.582 3.65 4.9 1.

Mean terminal half-life was slightly reduced in pediatric patients (range, 2.5 to 3 hours) in comparison with adults (range, 3 to 3.5 hours).

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics In normal adult volunteers, the following mean pharmacokinetic data have been determined following a single 0.15-mg/kg intravenous dose. Table 4. Pharmacokinetics in Normal Adult Volunteers Age-group (years) n Peak Plasma Concentration (ng/mL) Mean Elimination Half-life (h) Plasma Clearance (L/h/kg) 19-40 11 102 3.5 0.381 61-74 12 106 4.7 0.319 ≥ 75 11 170 5.5 0.262 Absorption A trial was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics of a single 4-mg dose administered as a 5-minute infusion compared with a single intramuscular injection.

Systemic exposure as measured by mean area under curve (AUC) were equivalent, with values of 156 [95% CI: 136, 180] and 161 [95% CI: 137, 190] ng•h/mL for intravenous and intramuscular groups, respectively. Mean peak plasma concentrations were 42.9 [95% CI: 33.8, 54.4] ng/mL at 10 minutes after intravenous infusion and 31.9 [95% CI: 26.3, 38.6] ng/mL at 41 minutes after intramuscular injection.

Distribution Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL. Circulating drug also distributes into erythrocytes. Elimination Metabolism: Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine.

The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron. The metabolites are observed in the urine.

In vitro metabolism studies have shown that ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 plays a predominant role while formation of the major in vivo metabolites is apparently mediated by CYP1A2. The role of CYP2D6 in ondansetron in vivo metabolism is relatively minor.

The pharmacokinetics of intravenous ondansetron did not differ between subjects who were poor metabolizers of CYP2D6 and those who were extensive metabolizers of CYP2D6, further supporting the limited role of CYP2D6 in ondansetron disposition in vivo. Excretion: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.

In a dose-proportionality trial, systemic exposure to 32 mg of ondansetron was not proportional to dose as measured by comparing dose-normalized AUC values with an 8-mg dose. This is consistent with a small decrease in systemic clearance with increasing plasma concentrations. Specific Populations Geriatric Patients: A reduction in clearance and increase in elimination half-life are seen in patients older than 75 years of age [see Use in Specific Populations (8.5)].

Pediatric Patients: Pharmacokinetic samples were collected from 74 cancer patients aged 6 to 48 months, who received a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses during a safety and efficacy trial. These data were combined with sequential pharmacokinetics data from 41 surgery patients aged 1 month to 24 months, who received a single dose of 0.1 mg/kg of intravenous ondansetron prior to surgery with general anesthesia, and a population pharmacokinetic analysis was performed on the combined data set.

The results of this analysis are included in Table 5 and are compared with the pharmacokinetic results in cancer patients aged 4 to 18 years. Table 5. Pharmacokinetics in Pediatric Cancer Patients Aged 1 Month to 18 Years Subjects and Age-group N CL (L/h/kg) Vd ss (L/kg) t ½ (h) Geometric Mean Mean Pediatric Cancer Patients 4 to 18 years N = 21 0.599 1.9 2.8 Population PK Patients 1 1 month to 48 months N = 115 0.582 3.65 4.9 1.

Population PK (Pharmacokinetic) Patients: 64% cancer patients and 36% surgery patients. Based on the population pharmacokinetic analysis, cancer patients aged 6 to 48 months who receive a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses would be expected to achieve a systemic exposure (AUC) consistent with the exposure achieved in previous pediatric trials in cancer patients (4 to 18 years) at similar doses.

In a trial of 21 pediatric patients (3 to 12 years) who were undergoing surgery requiring anesthesia for a duration of 45 minutes to 2 hours, a single intravenous dose of ondansetron, 2 mg (3 to 7 years) or 4 mg (8 to 12 years), was administered immediately prior to anesthesia induction. Mean weight-normalized clearance and volume of distribution values in these pediatric surgical patients were similar to those previously reported for young adults.

Mean terminal half-life was slightly reduced in pediatric patients (range, 2.5 to 3 hours) in comparison with adults (range, 3 to 3.5 hours). In a trial of 51 pediatric patients (aged 1 month to 24 months) who were undergoing surgery requiring general anesthesia, a single intravenous dose of ondansetron, 0.1 or 0.2 mg/kg, was administered prior to surgery.

As shown in Table 6, the 41 patients with pharmacokinetic data were divided into 2 groups, patients aged 1 month to 4 months and patients aged 5 to 24 months, and are compared with pediatric patients aged 3 to 12 years. Table 6. Pharmacokinetics in Pediatric Surgery Patients Aged 1 Month to 12 Years Subjects and Age-group N CL (L/h/kg) Vd ss (L/kg) t ½ (h) Geometric Mean Mean Pediatric Surgery Patients 3 to 12 years N = 21 0.439 1.65 2.9 Pediatric Surgery Patients 5 to 24 months N = 22 0.581 2.3 2.9 Pediatric Surgery Patients 1 month to 4 months N = 19 0.401 3.5 6.7 In general, surgical and cancer pediatric patients younger than 18 years tend to have a higher ondansetron clearance compared with adults leading to a shorter half-life in most pediatric patients.

In patients aged 1 month to 4 months, a longer half-life was observed due to the higher volume of distribution in this age-group. In a trial of 21 pediatric cancer patients (aged 4 to 18 years) who received three intravenous doses of 0.15 mg/kg of ondansetron at 4-hour intervals, patients older than 15 years exhibited ondansetron pharmacokinetic parameters similar to those of adults.

Patients with Renal Impairment: Due to the very small contribution (5%) of renal clearance to the overall clearance, renal impairment was not expected to significantly influence the total clearance of ondansetron. However, ondansetron mean plasma clearance was reduced by about 41% in patients with severe renal impairment (creatinine clearance < 30 mL/min).

This reduction in clearance is variable and was not consistent with an increase in half-life [see Use in Specific Populations (8.7)]. Patients with Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared with 5.7 hours in those without hepatic impairment.

In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), clearance is reduced 2-fold to 3-fold and apparent volume of distribution is increased with a resultant increase in half-life to 20 hours [see Dosage and Administration (2.3), Use in Specific Populations (8.6)]. Drug Interaction Studies CYP 3A4 Inducers: Ondansetron elimination may be affected by cytochrome P-450 inducers.

In a pharmacokinetic trial of 16 epileptic patients maintained chronically on CYP3A4 inducers, carbamazepine, or phenytoin, a reduction in AUC, C max, and t ½ of ondansetron was observed. This resulted in a significant increase in the clearance of ondansetron. In a pharmacokinetic study of 10 healthy subjects receiving a single-dose intravenous dose of ondansetron 8 mg after 600 mg rifampin once daily for five days, the AUC and the t ½ of ondansetron were reduced by 48% and 46%, respectively.

These changes in ondansetron exposure with CYP3A4 inducers are not thought to be clinically relevant [see Drug Interactions (7.3)]. Chemotherapeutic Agents: Carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron [see Drug Interactions (7.6)].

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ondansetron (as Hydrochloride) 2 mg/mL, 2 mL Ampule₱129.00–₱155.45Reference ₱145.75per ampuleDPRI procurement range
Ondansetron (as Hydrochloride) 2 mg/mL, 4 mL Ampule₱68.78–₱275.00Reference ₱78.23per ampuleDPRI procurement range
Ondansetron (as Hydrochloride) 8 mg Tablet₱65.00–₱95.00Reference ₱67.50per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ondansetron
PNF listingOral: 8 mg tablet (as hydrochloridedihydrate)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 2 mg/mL, 2 mL and 4 mL ampul (IM,IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. ONDANSETRON · Sportpharm LLC [US FDA-approved label, version 1, July 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de72f1ec-75dd-4659-a1a0-32b28b72c799
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .